Improvement of radiocephalic fistula maturation: rationale and design of the Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study - a randomized controlled trial

Bram M. Voorzaat, Jan van Schaik, Koen E. A. van der Bogt, Liffert Vogt, Laurens Huisman, Bas A. Th F. Gabreëls, Irene M. van der Meer, Randolph G. S. van Eps, Daniël Eefting, Marcel C. Weijmer, Han O. Groeneveld, Roos C. van Nieuwenhuizen, Henk Boom, Cornelis A. Verburgh, Karien van der Putten, Joris I. Rotmans

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


Non-maturation is a frequent complication of radiocephalic arteriovenous fistulas (RCAVF). In an animal model, liposomal prednisolone improved maturation of experimental fistulas. The Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study investigates if liposomal prednisolone improves RCAVF maturation. The LIPMAT study is an investigator-initiated, multicenter, double-blinded, placebo-controlled randomized controlled trial with 1:1 randomization to liposomal prednisolone or placebo. Eighty patients receiving an RCAVF will be included. The primary outcome is the cephalic vein diameter six weeks after surgery, measured by ultrasound. The LIPMAT study started in May 2016. Enrollment is expected to be completed by the end of 2017. The LIPMAT study is the first to evaluate the efficacy of liposomal prednisolone to enhance RCAVF maturation
Original languageEnglish
Pages (from-to)114-117
JournalJournal of Vascular Access
Issue numberSuppl. 1
Publication statusPublished - 2017

Cite this